Related Experiment Videos
[Hemophilia and acquired immunodeficiency].
1Diagnostics division, Abbott Laboratories, Abbott Park, North Chicago Illinois 60064.
La Revue Du Praticien
|December 21, 1989
Summary
French hemophiliacs contracted HIV from blood factor concentrates between 1980-1985. While viral inactivation reduced new infections, many develop AIDS, necessitating early antiviral therapy and education to prevent spread to partners.
Area of Science:
- Hematology
- Virology
- Public Health
Background:
- French hemophiliacs were infected with Human Immunodeficiency Virus (HIV) between 1980 and 1985.
- Initial infections were linked to American Factor VIII concentrates, followed by French Factor VIII and IX concentrates.
Purpose of the Study:
- To assess the impact of viral inactivation methods on HIV transmission in hemophiliacs.
- To highlight the development of clinical complications and the need for early intervention.
- To emphasize the importance of preventing further HIV spread.
Main Methods:
- Analysis of HIV infection rates in French hemophiliacs.
- Evaluation of the effectiveness of viral inactivation techniques in plasma derivatives.
- Monitoring of clinical complications related to immunodeficiency and Acquired Immunodeficiency Syndrome (AIDS).
Main Results:
- Viral inactivation methods appear to have interrupted HIV transmission, with current infection rates around 50%.
- A significant number of infected individuals are developing clinical immunodeficiency and AIDS.
- Biological tests can quantify viral replication and guide early antiviral therapy.
Conclusions:
- While viral inactivation has reduced HIV spread, a substantial portion of hemophiliacs remain infected.
- Early detection of viral replication is crucial for initiating timely antiviral treatment.
- Educational initiatives are vital to prevent HIV transmission to female partners of hemophiliacs.